Robatumumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Robatumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCD221
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6418H9960N1732O1992S42
Molar mass144602.93 g·mol−1
 ☒N☑Y (what is this?)  (verify)

Robatumumab (proposed INN; also known as SCH 717454 and MK-7454) is a monoclonal antibody and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor.[1]

Phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and Ewing's sarcoma are complete.[2][3] Merck has since discontinued development.[4]

References[edit]

  1. ^ "robatumumab", p. 337 in: Quality Assurance and Safety of Medicines (2008). Encrenaz C (ed.). "Proposed International Nonproprietary Names: List 100" (PDF). WHO Drug Information. 22 (4): 311–67.
  2. ^ Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, et al. (October 2016). "A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma". Pediatric Blood & Cancer. 63 (10): 1761–70. doi:10.1002/pbc.26087. PMC 5129487. PMID 27362300.
  3. ^ Clinical trial number NCT00551213 for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at ClinicalTrials.gov
  4. ^ "Robatumumab". Adis Insight. Springer Nature Switzerland AG.